ARCHIVES

Phase III Regorafenib Trial Meets PFS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Onward to 2010? NCI promises faster progress for more money.

May 20, 2005

NCI To Lose 382 Cancer FTEs; DCE Board Gets Response From Sullivan, But No Promises

July 21, 1989

IOM Panel Considering NCI Approach To Research In Minorities, Underserved

June 19, 1998

Tobacco Council Lists 14 Smoking-Health Awards

July 30, 1976

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

May 30, 2014

NCI May Give Up Positions From Other Programs To Meet Mandate For CTP Slots

October 19, 1979